Cargando…
Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer
Secondary malignancies are a known, albeit uncommon, complication of radiation for prostate cancer, either in the form of external beam radiotherapy or seed-implant brachytherapy. Of these secondary malignancies, mucinous adenocarcinoma of the prostatic urothelium is an extremely rare clinical entit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543121/ https://www.ncbi.nlm.nih.gov/pubmed/33088568 http://dx.doi.org/10.1177/2050313X20959867 |
_version_ | 1783591672006836224 |
---|---|
author | Peak, Taylor C Goodman, Michael M Fenu, Elena M Hemal, Ashok K |
author_facet | Peak, Taylor C Goodman, Michael M Fenu, Elena M Hemal, Ashok K |
author_sort | Peak, Taylor C |
collection | PubMed |
description | Secondary malignancies are a known, albeit uncommon, complication of radiation for prostate cancer, either in the form of external beam radiotherapy or seed-implant brachytherapy. Of these secondary malignancies, mucinous adenocarcinoma of the prostatic urothelium is an extremely rare clinical entity that has only once been reported in the literature. We report the case of an 80-year-old gentleman who initially underwent low-dose brachytherapy for low-risk prostate cancer 18 years ago. He subsequently developed recurrent gross hematuria and obstructive voiding symptoms. He underwent cystoscopy and transurethral resection of a large tumor from within the prostate. Final pathology of the tumor revealed a mucinous adenocarcinoma. Further immunostaining revealed this is likely to have originated from the prostatic urothelium. Given his age, comorbidities, and no clear data demonstrating that aggressive extirpative surgery provides a clinical benefit, we elected to undergo surveillance. Clinicians should be aware of mucinous adenocarcinoma of the prostatic urethra as an extremely rare, radiation-induced malignancy. Once a diagnosis is made, extirpative surgery is an option for localized disease, although prognosis remains poor. |
format | Online Article Text |
id | pubmed-7543121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-75431212020-10-20 Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer Peak, Taylor C Goodman, Michael M Fenu, Elena M Hemal, Ashok K SAGE Open Med Case Rep Case Report Secondary malignancies are a known, albeit uncommon, complication of radiation for prostate cancer, either in the form of external beam radiotherapy or seed-implant brachytherapy. Of these secondary malignancies, mucinous adenocarcinoma of the prostatic urothelium is an extremely rare clinical entity that has only once been reported in the literature. We report the case of an 80-year-old gentleman who initially underwent low-dose brachytherapy for low-risk prostate cancer 18 years ago. He subsequently developed recurrent gross hematuria and obstructive voiding symptoms. He underwent cystoscopy and transurethral resection of a large tumor from within the prostate. Final pathology of the tumor revealed a mucinous adenocarcinoma. Further immunostaining revealed this is likely to have originated from the prostatic urothelium. Given his age, comorbidities, and no clear data demonstrating that aggressive extirpative surgery provides a clinical benefit, we elected to undergo surveillance. Clinicians should be aware of mucinous adenocarcinoma of the prostatic urethra as an extremely rare, radiation-induced malignancy. Once a diagnosis is made, extirpative surgery is an option for localized disease, although prognosis remains poor. SAGE Publications 2020-10-04 /pmc/articles/PMC7543121/ /pubmed/33088568 http://dx.doi.org/10.1177/2050313X20959867 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Peak, Taylor C Goodman, Michael M Fenu, Elena M Hemal, Ashok K Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title | Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title_full | Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title_fullStr | Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title_full_unstemmed | Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title_short | Mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
title_sort | mucinous adenocarcinoma of the prostatic urethra following a remote history of primary brachytherapy for prostate cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543121/ https://www.ncbi.nlm.nih.gov/pubmed/33088568 http://dx.doi.org/10.1177/2050313X20959867 |
work_keys_str_mv | AT peaktaylorc mucinousadenocarcinomaoftheprostaticurethrafollowingaremotehistoryofprimarybrachytherapyforprostatecancer AT goodmanmichaelm mucinousadenocarcinomaoftheprostaticurethrafollowingaremotehistoryofprimarybrachytherapyforprostatecancer AT fenuelenam mucinousadenocarcinomaoftheprostaticurethrafollowingaremotehistoryofprimarybrachytherapyforprostatecancer AT hemalashokk mucinousadenocarcinomaoftheprostaticurethrafollowingaremotehistoryofprimarybrachytherapyforprostatecancer |